Dr. Xiao Zheng 郑晓
Chief Physician
Department of Thoracic Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy, chemotherapy, targeted and immunotherapy for esophageal, lung, breast, gastrointestinal, pancreatic cancers and lymphoma. Focus on concurrent chemoradiotherapy, radiosensitization, and radiobiology.
Dr. Zheng graduated from Wenzhou Medical College in 1982 and has practiced oncology radiation therapy for over 30 years. Training includes Shanghai Cancer Hospital and Mater Hospital in Brisbane, Australia. As Head of Radiation Therapy Ward 11 at Zhejiang Cancer Hospital, Dr. Zheng treats approximately 1,500 thoracic tumor patients annually, with expertise in head and neck, nasopharyngeal, lung, and esophageal cancers.
Professional roles
- Member, Esophageal Cancer Radiotherapy Committee, China Anti-Cancer Association
- Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Member, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Esophageal Cancer Professional Committee, Zhejiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Zheng Xiao). Papers usually list the name as Xiao Zheng or Zheng X.
Selected publications
24 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Jpn J Clin Oncol, 2021 (senior author): MiR-30a sensitized lung cancer against neoadjuvant chemotherapy by depressing autophagy. PubMed 33537721
- Transl Cancer Res, 2019 (senior author): The clinical value of circulating tumor DNA detection in advanced non-small cell lung cancer. PubMed 35116746
- Oncol Lett, 2017 (senior author): Decreased expression of CD63 tetraspanin protein predicts elevated malignant potential in human esophageal cancer. PubMed 28599425
- Oncol Lett, 2014 (first author): A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy. PubMed 25202368
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion